1. Scrip
  2. >>Business

Geron’s Potential Blockbuster Imetelstat Faces Unexpected AdComm In MDS

Before 2024 PDUFA Date

 
• By Ayisha Sharma

Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.  

red blood cells
Around 50% Of MDS Patients Experience Thrombocytopenia • Source: Shutterstock
Key Takeaways:

  • The AdComm meeting will take place prior to the drug’s PDUFA date of 16 June 2024.

In an unexpected twist, Geron Corporation’s first-in-class telomerase inhibitor imetelstat for anemia in patients with lower risk myelodysplastic syndromes (MDS) will be subject to a US Food and Drug Administration advisory committee meeting prior to a 16 June 2024 action date.

Imetelstat is designed to stop the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies. Earlier this...

More from Business

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.